Trial · NCT04281472
Results by group125
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 125
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) | Stage A: Efgartigimod PH20 SC | 66.5 | 95% Confidence Interval 61.0 to 71.6 | percentage of participants | |
| Stage B: Time to First Adjusted INCAT Deterioration Compared to Stage B Baseline | Stage B: Efgartigimod PH20 SC | NA | 95% Confidence Interval NA to NA | Days | |
| Stage B: Time to First Adjusted INCAT Deterioration Compared to Stage B Baseline | Stage B: Placebo PH20 SC | 140.0 | 95% Confidence Interval 75.0 to NA | Days | |
| Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI) | Stage A: Efgartigimod PH20 SC | 25th percentile | 22 | 95% Confidence Interval 22.0 to 23.0 | days |
| Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI) | Stage A: Efgartigimod PH20 SC | 50th percentile (median) | 43.0 | 95% Confidence Interval 31.0 to 51.0 | days |
| Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI) | Stage A: Efgartigimod PH20 SC | 75th percentile | 71.0 | 95% Confidence Interval 70.0 to 78.0 | days |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Adjusted INCAT Score | Stage A: Efgartigimod PH20 SC | -0.9 | Standard Deviation 1.71 | score on a scale | |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Medical Research Council (MRC) Sum Score | Stage A: Efgartigimod PH20 SC | 3.8 | Standard Error 0.41 | score on a scale | |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in I-RODS Disability Scores | Stage A: Efgartigimod PH20 SC | 7.7 | Standard Deviation 15.48 | score on a scale | |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in TUG Score | Stage A: Efgartigimod PH20 SC | -4.3 | Standard Error 0.83 | seconds | |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Mean Grip Strength | Stage A: Efgartigimod PH20 SC | dominant hand | 12.3 | Standard Deviation 18.68 | Kilopascal (kPa) |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Mean Grip Strength | Stage A: Efgartigimod PH20 SC | nondominant hand | 11.2 | Standard Deviation 21.12 | Kilopascal (kPa) |
| Stage A: Exposure Adjusted Occurrence of Treatment-emergent Adverse Events and Serious Adverse Events | Stage A: Efgartigimod PH20 SC | Exposure Adjusted Occurrence of Treatment-emergent Adverse Events | 1343.1 | Events/100 PYFU | |
| Stage A: Exposure Adjusted Occurrence of Treatment-emergent Adverse Events and Serious Adverse Events | Stage A: Efgartigimod PH20 SC | Exposure Adjusted Occurrence of Treatment-emergent Serious Adverse Events | 51.2 | Events/100 PYFU | |
| Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time | Stage A: Efgartigimod PH20 SC | Week 1 | 14.9 | Standard Deviation 6.92 | ug/mL |
| Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time | Stage A: Efgartigimod PH20 SC | Week 2 | 19.6 | Standard Deviation 8.55 | ug/mL |
| Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time | Stage A: Efgartigimod PH20 SC | Week 3 | 19.7 | Standard Deviation 9.62 | ug/mL |
| Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time | Stage A: Efgartigimod PH20 SC | Week 4 | 18.9 | Standard Deviation 9.96 | ug/mL |
| Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time | Stage A: Efgartigimod PH20 SC | Week 5 | 18.4 | Standard Deviation 8.38 | ug/mL |
| Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time | Stage A: Efgartigimod PH20 SC | Week 6 | 19.2 | Standard Deviation 9.62 | ug/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04281472/results